Eli Lilly and Co is slated to unveil its second-quarter 2023 results on Tuesday (August 8), prior to the market opening, with Wall Street expecting earnings of $1.98 a share.
That's up around 9% on the same period last year, and 15% ahead of the first quarter.
Investors will be keenly observing the performance of the company's key growth drugs, such as Trulicity, Taltz, Verzenio, Jardiance, and Emgality.
The Zacks consensus estimate for revenue from these drugs stands at $2.09 billion, $673 million, $908 million, $655 million, and $170 million respectively.
The absence of any Covid antibody revenues and the entry of generics for chemotherapy Alimta are expected to have put the brakes on slightly.
Finally, analysts will be keen on updates regarding donanemab, Lilly's treatment for early-stage Alzheimer's disease.